JP2022520998A - アルブミン結合抗体及びその使用 - Google Patents

アルブミン結合抗体及びその使用 Download PDF

Info

Publication number
JP2022520998A
JP2022520998A JP2021549227A JP2021549227A JP2022520998A JP 2022520998 A JP2022520998 A JP 2022520998A JP 2021549227 A JP2021549227 A JP 2021549227A JP 2021549227 A JP2021549227 A JP 2021549227A JP 2022520998 A JP2022520998 A JP 2022520998A
Authority
JP
Japan
Prior art keywords
amino acid
seq
acid sequence
albumin
variant
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2021549227A
Other languages
English (en)
Japanese (ja)
Other versions
JPWO2020172528A5 (enExample
Inventor
ゾング ジヤング
イー ファン
シーゲル マシュー
フアング ジアニング
リアオ エリック
リー エラ
Original Assignee
アンウィタ バイオサイエンシス， インク．
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by アンウィタ バイオサイエンシス， インク． filed Critical アンウィタ バイオサイエンシス， インク．
Publication of JP2022520998A publication Critical patent/JP2022520998A/ja
Publication of JPWO2020172528A5 publication Critical patent/JPWO2020172528A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/76—Albumins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/22—Immunoglobulins specific features characterized by taxonomic origin from camelids, e.g. camel, llama or dromedary
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Biophysics (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
JP2021549227A 2019-02-22 2020-02-21 アルブミン結合抗体及びその使用 Pending JP2022520998A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962809475P 2019-02-22 2019-02-22
US62/809,475 2019-02-22
PCT/US2020/019215 WO2020172528A1 (en) 2019-02-22 2020-02-21 Albumin binding antibodies and use thereof

Publications (2)

Publication Number Publication Date
JP2022520998A true JP2022520998A (ja) 2022-04-04
JPWO2020172528A5 JPWO2020172528A5 (enExample) 2023-02-28

Family

ID=72144485

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2021549227A Pending JP2022520998A (ja) 2019-02-22 2020-02-21 アルブミン結合抗体及びその使用

Country Status (6)

Country Link
US (1) US12479909B2 (enExample)
EP (1) EP3927740A4 (enExample)
JP (1) JP2022520998A (enExample)
CN (1) CN113508134B (enExample)
TW (1) TW202045545A (enExample)
WO (1) WO2020172528A1 (enExample)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11629340B2 (en) 2017-03-03 2023-04-18 Obsidian Therapeutics, Inc. DHFR tunable protein regulation
JP2021527706A (ja) * 2018-06-18 2021-10-14 アンウィタ バイオサイエンシス， インク． 抗メソテリンコンストラクト及びその使用
WO2021102063A1 (en) 2019-11-20 2021-05-27 Anwita Biosciences, Inc. Cytokine fusion proteins, and their pharmaceutical compositions and therapeutic applications
EP4143329A4 (en) 2020-04-28 2024-10-16 Anwita Biosciences, Inc. Interleukin-2 polypeptides and fusion proteins thereof, and their pharmaceutical compositions and therapeutic applications
EP4171611A4 (en) 2020-07-30 2024-10-02 Anwita Biosciences, Inc. Interleukin-22 fusion proteins, and their pharmaceutical compositions and therapeutic applications
CN116419973A (zh) * 2020-10-02 2023-07-11 新加坡科技研究局 用于蛋白质生产和筛选的表达系统
WO2022104236A2 (en) * 2020-11-16 2022-05-19 Ab Therapeutics, Inc. Multispecific antibodies and uses thereof
JP2023552462A (ja) * 2020-12-08 2023-12-15 ジャナックス セラピューティクス，インク． 半減期延長組成物および方法
CN117545504A (zh) * 2021-06-07 2024-02-09 上海济煜医药科技有限公司 抗人血清白蛋白的抗原结合蛋白
WO2023215810A1 (en) * 2022-05-05 2023-11-09 Inhibrx, Inc. Albumin-binding polypeptides and uses thereof
JP2025526875A (ja) * 2022-08-17 2025-08-15 アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル 改善された抗アルブミンナノボディおよびその使用
WO2024051796A1 (en) * 2022-09-09 2024-03-14 Wuxi Biologics (Shanghai) Co., Ltd. Albumin binding proteins, fusion proteins and uses thereof
WO2024097639A1 (en) * 2022-10-31 2024-05-10 Modernatx, Inc. Hsa-binding antibodies and binding proteins and uses thereof
WO2024170756A1 (en) 2023-02-17 2024-08-22 Ablynx N.V. Polypeptides binding to the neonatal fc receptor
WO2024236068A1 (en) * 2023-05-17 2024-11-21 Navigo Proteins Affinity ligand for a single chain antibody fragment specific for serum albumin
NL2036011B1 (en) 2023-10-12 2025-04-30 Synapse Res Institute Molecules for reversing anti-coagulant activity of direct oral anticoagulants

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2012532620A (ja) * 2009-07-16 2012-12-20 グラクソ グループ リミテッド 改良型抗血清アルブミン結合単一可変ドメイン
JP2013537421A (ja) * 2010-08-20 2013-10-03 グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッド 改良された抗血清アルブミン結合変異体
WO2017201488A1 (en) * 2016-05-20 2017-11-23 Harpoon Therapeutics, Inc. Single domain serum albumin binding protein
JP2018517431A (ja) * 2015-05-21 2018-07-05 ハープーン セラピューティクス，インク． 三重特異性結合タンパク質と使用方法
JP2019502656A (ja) * 2015-11-13 2019-01-31 アブリンクス エン．ヴェー． 改善された血清アルブミン結合性免疫グロブリン可変ドメイン

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1558646A2 (en) * 2002-11-08 2005-08-03 Ablynx N.V. Single domain antibodies directed against interferon- gamma and uses thereof
US9156914B2 (en) * 2006-12-19 2015-10-13 Ablynx N.V. Amino acid sequences directed against a metalloproteinase from the ADAM family and polypeptides comprising the same for the treatment of ADAM-related diseases and disorders
EP2692736B1 (en) * 2008-10-14 2018-04-18 National Research Council Of Canada Bsa-specific antibodies
US9556273B2 (en) 2010-03-29 2017-01-31 Vib Vzw Anti-macrophage mannose receptor single variable domains for targeting and in vivo imaging of tumor-associated macrophages
US9670275B2 (en) * 2012-01-23 2017-06-06 Ablynx N.V. Sequences directed against hepatocyte growth factor (HGF) and polypeptides comprising the same for the treatment of cancers and/or tumors
DK3564260T5 (da) 2012-02-15 2024-09-02 Bioverativ Therapeutics Inc Faktor viii-sammensætninger og fremgangsmåder til fremstilling og anvendelse deraf
WO2016034968A1 (en) * 2014-09-02 2016-03-10 Pfizer Inc. Therapeutic antibody
WO2016081639A1 (en) * 2014-11-19 2016-05-26 Genentech, Inc. Antibodies against bace1 and use thereof for neural disease immunotherapy
RU2022101604A (ru) * 2016-12-07 2022-03-29 Аблинкс Нв Улучшенные отдельные вариабельные домены иммуноглобулина, связывающиеся с сывороточным альбумином
KR102376863B1 (ko) 2017-05-12 2022-03-21 하푼 테라퓨틱스, 인크. 메소텔린 결합 단백질
UY37829A (es) * 2017-08-03 2019-01-31 Amgen Inc Muteínas de interleucina 21 y métodos de tratamiento
CA3076250A1 (en) * 2017-10-02 2019-04-11 Vib Vzw Compounds to inhibit bacterial s-layer protein assembly
JP2021527706A (ja) 2018-06-18 2021-10-14 アンウィタ バイオサイエンシス， インク． 抗メソテリンコンストラクト及びその使用
WO2021102063A1 (en) * 2019-11-20 2021-05-27 Anwita Biosciences, Inc. Cytokine fusion proteins, and their pharmaceutical compositions and therapeutic applications
EP4171611A4 (en) * 2020-07-30 2024-10-02 Anwita Biosciences, Inc. Interleukin-22 fusion proteins, and their pharmaceutical compositions and therapeutic applications

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2012532620A (ja) * 2009-07-16 2012-12-20 グラクソ グループ リミテッド 改良型抗血清アルブミン結合単一可変ドメイン
JP2013537421A (ja) * 2010-08-20 2013-10-03 グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッド 改良された抗血清アルブミン結合変異体
JP2018517431A (ja) * 2015-05-21 2018-07-05 ハープーン セラピューティクス，インク． 三重特異性結合タンパク質と使用方法
JP2019502656A (ja) * 2015-11-13 2019-01-31 アブリンクス エン．ヴェー． 改善された血清アルブミン結合性免疫グロブリン可変ドメイン
WO2017201488A1 (en) * 2016-05-20 2017-11-23 Harpoon Therapeutics, Inc. Single domain serum albumin binding protein

Also Published As

Publication number Publication date
TW202045545A (zh) 2020-12-16
US20220195021A1 (en) 2022-06-23
WO2020172528A8 (en) 2021-10-07
CN113508134A (zh) 2021-10-15
CN113508134B (zh) 2024-12-03
EP3927740A1 (en) 2021-12-29
WO2020172528A1 (en) 2020-08-27
US12479909B2 (en) 2025-11-25
EP3927740A4 (en) 2023-03-01

Similar Documents

Publication Publication Date Title
CN113508134B (zh) 白蛋白结合抗体及其用途
JP7544937B2 (ja) Ｔｉｇｉｔに対する単一ドメイン抗体及びその変異体
JP7314356B2 (ja) 改変ｊ鎖を有する結合分子
CN111699200B (zh) 针对pd-1的单域抗体和其变体
JP7346790B2 (ja) Ｌａｇ‐３に対する単一ドメイン抗体およびその使用
WO2019096121A1 (en) Single-domain antibodies and variants thereof against pd-l1
US20140079701A1 (en) Linker peptides and polypeptides comprising same
JP2022523710A (ja) Ｃｄ４４に特異的な抗体
TWI870360B (zh) 雙特異性抗體構建體之下游加工
WO2023030511A1 (en) Bi-functional fusion protein and uses thereof
TW202542185A (zh) 具有增強的效應功能之ｇｐｒｃ５ｄ抗體及其用途
TW202412838A (zh) 包含結合γ-δ T細胞受體之抗體之組合物
CN119350502A (zh) 靶向fap的抗原结合蛋白及其应用

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20211210

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230216

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20230216

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20240109

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20240806